OTC:EMED
Electromedical Technologies, Inc
A niche healthcare technology provider specializing in electromedical equipment for clinical diagnostics and patient monitoring with a global footprint.
Key Metrics
Investment Thesis
Bull Case
Investors may view EMED as a turnaround opportunity given its improving net loss trajectory and steady revenue growth in a resilient healthcare demand environment. The company's proprietary technology portfolio offers potential for margin expansion if they can successfully reduce operating costs and improve cash conversion ratios. At current valuations, the stock trades at a discount to peers, potentially offering significant upside if management executes a successful cost-cutting or financing strategy.
Bear Case
The stock carries severe fundamental risks due to negative net profit of -$2.6M, accumulated deficit of -$27.5M, and current liabilities exceeding total assets by over $3 million. High interest expense of nearly $900k combined with limited cash reserves of only $87k creates an urgent need for equity dilution or debt restructuring that could erode shareholder value. Without a clear path to profitability or positive cash flow generation, the company faces existential threats from credit rating downgrades and inability to meet debt obligations.
About Electromedical Technologies, Inc
Electromedical Technologies, Inc. (EMED) operates within the healthcare technology sector, providing specialized electromedical equipment to hospitals, clinics, and diagnostic centers globally. The company leverages a portfolio of proprietary devices designed for advanced medical imaging and patient monitoring solutions. With operations spanning North America and international markets, EMED focuses on delivering innovative tools that enhance clinical diagnostics and operational efficiency.
Analysis
Management Discussion
Despite a slight improvement in net loss from -$3.5M in 2022 to -$2.6M in 2023, the company continues to operate with negative operating cash flow of -$1.4M and a significant cash burn rate. Total liabilities of $3.6M exceed total assets, resulting in negative shareholders' equity of -$2.9M, which raises concerns about long-term financial sustainability. While revenue growth from $1.1M to $1.3M shows top-line traction, the inability to convert this into positive cash flow or profitability remains a critical operational challenge.
Industry Overview
The electromedical equipment industry is characterized by high barriers to entry due to stringent regulatory requirements like FDA approval and complex supply chain logistics for medical-grade components. Market growth is driven by aging populations and increasing demand for advanced diagnostic imaging technologies in both developed and emerging markets. However, the sector faces intense competition from established giants and generic manufacturers, leading to pricing pressures and long product development cycles.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 |
|---|---|---|
| Revenue | $1.1M | $1.3M |
| Cost of Revenue | $261.2K | $303.3K |
| Gross Profit | $888.6K | $1.0M |
| Operating Expenses | $2.5M | $3.1M |
| Operating Income | $-1.6M | $-2.1M |
| R&D | $92.3K | $231.4K |
| G&A | $2.5M | $3.1M |
| Stock-Based Comp | $509.6K | $715.0K |
| D&A | $21.9K | $4.6K |
| Other OpEx | $-92.3K | $-231.4K |
| Non-Operating Income | $0 | $0 |
| Interest Expense | $791.1K | $893.2K |
| Pre-Tax Income | $-1.6M | $-2.1M |
| Income Tax | $1.9M | $576.3K |
| Continuing Ops | $-3.5M | $-2.6M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-3.5M | $-2.6M |
| Minority Interest | $0 | $0 |
| Net to Common | $-3.5M | $-2.6M |
| Metric | 2022 | 2023 |
|---|---|---|
| Current Assets | $647.8K | $449.2K |
| Cash & Equivalents | $368.4K | $87.7K |
| Accounts Receivable | $9.4K | $4.4K |
| Inventory | $62.1K | $68.5K |
| Prepaid Expenses | — | $288.6K |
| Other Current Assets | $207.9K | $0 |
| Long-Term Assets | $705.5K | $299.2K |
| PP&E (Net) | $705.5K | $149.7K |
| Operating Leases | — | $149.5K |
| Other LT Assets | $0 | $0 |
| Total Assets | $1.4M | $748.4K |
| Current Liabilities | $2.9M | $3.4M |
| Accounts Payable | $266.7K | $239.5K |
| Deferred Revenue | $217.6K | $197.3K |
| Other Current Liab | $2.2M | $2.9M |
| Long-Term Liabilities | $649.9K | $264.6K |
| Total Liabilities | $3.6M | $3.6M |
| Shareholders' Equity | $-2.2M | $-2.9M |
| Paid-In Capital | $22.2M | $23.8M |
| Retained Earnings | $-24.8M | $-27.5M |
| Total L&E | $1.4M | $748.4K |
| Metric | 2022 | 2023 |
|---|---|---|
| Net Income (CFO) | $-3.5M | $-2.6M |
| Non-Cash Adjustments | $2.6M | $524.2K |
| Working Capital Changes | $67.3K | $699.6K |
| Cash from Operations | $-773.3K | $-1.4M |
| Capital Expenditures | — | $149.7K |
| Cash from Investing | $0 | $1.7M |
| Cash from Financing | $758.6K | $-608.2K |
| FX Effect | $0 | $0 |
| Net Change in Cash | $-14.7K | $-280.7K |
| Beginning Cash | $383.2K | $368.4K |
| Ending Cash | $368.4K | $87.7K |
Frequently Asked Questions
How does Electromedical Technologies, Inc make money?
The company derives revenue primarily from the sale of proprietary electromedical devices to hospital networks and diagnostic imaging centers. A secondary revenue stream comes from after-sales services, including maintenance contracts and technical support for installed medical equipment. The firm also generates income through strategic licensing agreements and partnerships that allow third parties to distribute its specialized medical technology.
What are the main risks for EMED?
Persistent negative operating cash flow indicates potential liquidity constraints that could hinder ability to fund future growth or sustain operations without external capital raises. The company carries a significant retained earnings deficit and substantial interest expense relative to its current assets, signaling high financial leverage and solvency concerns. Revenue concentration in specialized medical equipment creates exposure to regulatory changes, reimbursement rate cuts, or shifts in hospital procurement budgets.
What is EMED's competitive advantage?
The company possesses a deep proprietary technology moat through years of R&D investment in specialized electromedical engineering that is difficult for competitors to replicate. Established long-term relationships with major hospital systems create high switching costs due to the integration of their equipment into existing clinical workflows and IT infrastructure. Strong brand reputation in niche medical imaging segments provides pricing power and customer loyalty despite the competitive nature of the healthcare technology market.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.